Nath Bio-Genes (India) Ltd

Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹271.00 crores, reported a consolidated net profit of ₹1.60 crores for Q3 FY26 (October-December 2025), representing a sharp 66.80% decline quarter-on-quarter and a 39.62% fall year-on-year. Despite a robust 78.90% YoY revenue increase to ₹65.96 crores driven by seasonal demand, the company's profitability deteriorated significantly as operating margins compressed and interest costs surged to their highest quarterly levels.

Nath Bio-Genes (India) Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 07 Jan 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 27 January 2026, providing investors with the latest perspective on the company’s performance and prospects.

Nath Bio-Genes (India) Ltd’s shares declined sharply to a new 52-week low of Rs.139.8 on 20 Jan 2026, marking a significant downturn amid broader market weakness and sectoral pressures. The stock underperformed its sector and key market indices, reflecting ongoing concerns about the company’s financial performance and investor sentiment.

Nath Bio-Genes (India) Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 2 January 2026, driven primarily by a shift in technical indicators despite ongoing fundamental challenges. The company’s Mojo Score now stands at 31.0, reflecting a cautious but improved outlook amid mixed financial and market signals.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 January 2026, providing investors with the most recent and relevant data to assess the company's outlook.

Nath Bio-Genes (India), a player in the Other Agricultural Products sector, has experienced a shift in market evaluation driven by a combination of technical indicators, valuation metrics, financial trends, and broader market participation. This article analyses the factors influencing the recent revision in the company’s assessment, highlighting key data points and contextualising its performance against sector and market benchmarks.

Nath Bio-Genes (India) has reached a fresh 52-week low of Rs.140.1, marking a significant decline amid a sustained downward trend over recent sessions. The stock’s performance contrasts sharply with broader market gains, reflecting ongoing pressures within the company’s sector and financial metrics.

Nath Bio-Genes (India) has reached a new 52-week low of Rs.140.1, marking a significant decline amid a sustained downward trend over recent sessions. The stock’s performance contrasts sharply with broader market gains, reflecting ongoing pressures within the company’s financial and operational metrics.

Nath Bio-Genes has experienced a revision in its market evaluation, reflecting shifts in its fundamental and technical outlook. The company’s recent performance metrics and investor participation trends have contributed to this updated assessment, signalling caution for stakeholders in the Other Agricultural Products sector.

Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹320.00 crores, reported a consolidated net profit of ₹2.75 crores for Q2 FY26 (Jul-Sep'25), representing a sharp 92.62% quarter-on-quarter decline but a robust 147.75% year-on-year improvement. The dramatic sequential fall reflects the company's highly seasonal business model, where the first quarter typically captures the bulk of annual revenues during the peak agricultural season.

Nath Bio-Genes (India) has undergone a recent evaluation adjustment, reflecting a shift in its technical outlook. The company has reported a -10.61% return over the past year and a decline in institutional investor participation. Additionally, it has experienced a -0.69% CAGR growth in operating profits over five years.

Nath Bio-Genes (India) has recently experienced a change in its evaluation, with its technical trend shifting to mildly bearish. The company reported flat financial performance for the quarter ending June 2025, and its five-year operating profit CAGR stands at -0.69%. Institutional investor participation has declined, reflecting cautious sentiment.

Nath Bio-Genes (India) has recently experienced a score revision reflecting a bearish outlook. The company's performance shows a -9.05% return over the past year, contrasting with the Sensex's 5.78% gain. Long-term growth metrics indicate challenges, while the stock trades at a discount relative to peers.